長時間作用型注射剤市場

当レポートでは、世界の長時間作用型注射剤市場について調査し、市場の概要とともに、製剤技術の概要、治療分野、および市場に参入する企業の競合動向などを提供しています。

目次

エグゼクティブサマリー

注射剤製剤技術

• 注射型デバイス設計における技術革新
• 治療需要の促進要因

市場要因

• 患者コンプライアンス
• 使いやすさ
• ヘルスケア規則
• マネージドケアの取り組み
• 競合情勢
• 危険因子

製剤技術

• 生分解性ポリマー
• PEG
• PLA/PLGA
• ポリエーテルエステル
• 長時間作用型注射剤
  • 製剤技術
• BEPO (MedinCell)
• ChroniJect (Oakwood Laboratories/PharmaSophia)
• CriticalMix (Critical Pharmaceuticals)
• Depofoam (Pacira)
• FluidCrystal (Camarus)
• LinkeRx (Alkermes)
• Medisorb (Alkermes)
• Medusa (Recipharm/Avadel)
• Nanocrystals (Alkermes)
• Optisomes (Talon/Spectrum)
• PolyActive (Octoplus)
• Q-Sphera (Midatech Pharma)
• SABER/SAIB (DURECT)
• SynBiosys (Innocore)
• TransCon (Ascendis)

物理的プロセス管理方法

長時間作用型注射剤- 開発要因

• 配合要因
• 安定
• 管理要因

長時間作用型製品の分析

治療セクター分析

• 中毒
• 血糖コントロール
• 感染症
• 肝炎
• 神経学
• 統合失調症
• 双極性障害
• 腫瘍
• 疼痛管理
• 生殖医療
• 不妊
• 子宮内膜症

企業プロファイル

Engineered Injectables that Address Chronic Conditions

Chronic conditions require drug administration over long periods of time, placing a greater emphasis on self-administration. With the shift away from caregiver interaction, drug safety and compliance/adherence become prominent concerns. These concerns, which are not new, are becoming magnified as the number of powerful new drugs reaching the market increases. For healthcare managers and public health officials, one way to address these issues is less frequent dosing. Using formulation technologies designed to modulate the effect of therapeutic substances, drug developers are creating formulations that exhibit extended release profiles. These chemistries include polymers such as polyethylene glycol-complexed (PEGylated), which are used to product encapsulated and coated versions of new APIs. The goal is to address the requirement for patient-dependent, and therefore compliance-sensitive, drug treatment protocols such as multiple dosing through controlled release formulations that provide the desired therapeutic effect with less-frequent dosing.

What You Will Learn:

• What are the marketed long-acting injectable drug products, what long-acting formulation technologies are used, and who markets them?

• What are the major factors driving long-acting injectable drug demand?

• What long-acting injectable drug candidates are in late-stage clinical development and what is their potential impact?

• How important are drug developer-formulation technologist relationships in the long-acting market segment, and what are the key alliances in the industry?

• What are the essential formulation factors, delivery device selection issues, related technology factors and market development issues for long-acting injectable drug products?

• In what therapeutic market segments do long-acting injectables compete? What is their market share today? What will it be in 2028? What is their expected growth rate?

• What are the significant economic, technology, and regulatory factors affecting the market for long-acting injectable drugs?

Table of Contents

Executive Summary

• Executive Summary
• Long-Acting Injectable Drugs
• Executive Summary
• Injectable Drug Market Dynamics
• The Trend toward Self-Administration

Injectable Drug Formulation Technology

• Innovation in Injectable Device Designs
• Therapeutic Demand Drivers

Market Factors

• Patient Compliance
• Ease of Use
• Healthcare Regulations
• Managed Care Initiatives
• Competitive Landscape
• Risk Factors

Formulation Technologies

• Biodegradable Polymers
• PEG
• PLA/PLGA
• Polyether ester
• Long-Acting Injectable
  • Formulation Technologies
• BEPO (MedinCell)
• ChroniJect (Oakwood Laboratories/PharmaSophia)
• CriticalMix (Critical Pharmaceuticals)
• Depofoam (Pacira)
• FluidCrystal (Camarus)
• LinkeRx (Alkermes)
• Medisorb (Alkermes)
• Medusa (Recipharm/Avadel)
• Nanocrystals (Alkermes)
• Optisomes (Talon/Spectrum)
• PolyActive (Octoplus)
• Q-Sphera (Midatech Pharma)
• SABER/SAIB (DURECT)
• SynBiosys (Innocore)
• TransCon (Ascendis)

Physical Process Control Methods

• Supercritical Fluid
• SCF for Nanoparticle Formulations
• Formulplex (Supercritical Solutions)
• Ferro SCF extraction of emulsions (SFEE)

Long-Acting Injectables - Development Factors

• Formulation Factors
• Stability
• Administration Factors

Long-Acting Product Analysis

• Aripiprazole
• Aripiprazole lauroxil
• Bupivacaine
• Buprenorphine
• Cytarabine
• Cytarabine & Daunorubicin
• Doxorubicin
• Estradiol
• Exenatide
• Fluphenazine decanoate
• Goserelin acetate
• Granisetron
• Interferon (1)
• Interferon (2)
• Interferon (3)
• Interferon (4)
• Irinotecan
• Lanreotide acetate
• Leuprolide
• Leuprolide Depot
• Medroxyprogesterone
• Naltrexone
• Octreotide acetate
• Olanzapine Pamoate
• Paliperidone palmitate
• Pasireotide
• Pegvaliase-pqpz
• Risperidone
• Testosterone
• Triptorelin (1)
• Triptorelin (2)
• Triamcinolone acetonide
• Vincristine sulfate
• Glycemic Control
• AB101 (Rezolute)
• Hormone Deficiency
• human Growth Hormone/ Ascendis Pharma
• Addiction
• CAM2038 (Camurus)
• Pain Management
• Posidur/Durect
• Cardiology
• Treprostinil/Ascendis Pharma
• Neurology
• Relday/Risperidone (DURECT/Zogenix)
• Oncology
• CAM2032 (Camurus)

Therapeutic Sector Analysis

• Addiction
• Glycemic Control
• Infectious Disease
• Hepatitis
• Neurology
• Schizophrenia
• Bipolar Disorder
• Oncology
• Pain Management
• Reproductive Health
• Fertility
• Endometriosis

Company Profiles